Naylor et al. systematically review the efficacy of treatments for beta-cell monogenic diabetes. Limited evidence from the mostly non-randomized, small studies supports no treatment in glucokinase-related hyperglycemia and sulfonylureas for HNF1A-diabetes; further evidence is needed on the optimum treatments in these and other monogenic subtypes.
- Rochelle N. Naylor
- Kashyap A. Patel
- Tiinamaija Tuomi